Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimura + Anti-VEGF in Wet AMD
NCT05571267Phase 2Terminated
- Sponsor
- IVERIC bio
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- RNA Aptamers, DNA Aptamers
01
Overview
Phase 2, randomised, open-label trial of avacincaptad pegol in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by IVERIC bio. Primary endpoints: Percentage of Participants With >0 Letter Loss at 18 months, Percentage of Participants With >5 Letter Loss at 18 months and 1 more. Started Oct 2016; status: terminated.
02
Drugs
avacincaptad pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05571267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571267.